Stryker CEO Lobo skeptical on 'repless' generic sales models (MassDevice)
Stryker CEO Kevin Lobo says he doesn't view the so-called 'repless' generic sales models piloted by orthopedic rivals Smith & Nephew and Wright Medical as a serious threat.
Stryker (NYSE:SYK) CEO Kevin Lobo is skeptical of so-called "repless" generic sales models for orthopedic procedures, he said today, even as rival (and potential acquisition) Smith & Nephew(FTSE:SN, NYSE:SNN) looks to expand its no-frills Syncera program.
Lobo, speaking at the J.P. Morgan Healthcare Conference in San Francisco, said that he's ...
